Previous 10 | Next 10 |
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an...
Dr. Reddy’s Laboratories (NYSE: RDY ) has announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis. More news on: Dr. Reddy's Laboratories Limited, Healthcare stocks news, Read m...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate...
Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended March 31, 2019 was filed with the United States Securities and Exchange Commis...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the re-launch of Zenatane ® (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg, a therapeutic ...
Dr. Reddy's Laboratories (NYSE: RDY ) slips 5% premarket on light volume on the heels of downgrades despite its fiscal Q4 beat . More news on: Dr. Reddy's Laboratories Limited, Healthcare stocks news, Stocks on the move, Read more ...
Dr. Reddy's Laboratories Ltd (RDY) Q4 2019 Earnings Conference Call May 17, 2019, 08:30 ET Company Participants Amit Agarwal - Director, Finance, FP&A & IR Gunupati Prasad - CEO Saumen Chakraborty - CFO Erez Israeli - COO Anil Namboodiripad - SVP, Head, Proprietary Pr...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2019 under International Financial Reporting Standards (IFRS). Commenting on the results, CEO and Co-chai...
The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2019 Q4 earnings Read more ...
Dr. Reddy's ( RDY ) Q4 results : Revenues: $581M (+13.7%). More news on: Dr. Reddy's Laboratories Limited, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2024. The information mentioned in this release is based on consolidated financial statements under International Fina...
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...